MedTrace Logo

Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals

NCT07433387 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-11

No results posted yet for this study

Summary

An Exploratory Multicenter, Open-label, Sequential Cohort Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetic Characteristics of LP-98 for Injection in Antiretroviral Therapy-Naive HIV-Infected Individuals

Conditions

Interventions

DRUG

LP-98 20 mg

The study plans to enroll a total of 30 subjects, with 10 subjects in each cohort. Enrolled subjects will receive LP-98 treatment at doses of 20 mg, 40 mg, or 80 mg according to their assigned cohort. The drug will be administered via subcutaneous injection, with an interval of 14 days between doses, for a total of 4 doses.

DRUG

LP-98 40 mg

LP-98 40 mg

DRUG

LP-98 80 mg

LP-98 80 mg

Sponsors & Collaborators

  • Institute of Pathogen Biology, Beijing, China

    collaborator OTHER

  • Shanxi Kangbao Biological Product Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ping Ma, Doctor · Tianjin Second People's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-29
Primary Completion
2026-07-10
Completion
2026-09-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07433387 on ClinicalTrials.gov